- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04828707
Assessment of Safety and Efficacy of Nerivio for the Migraine Prevention
A Prospective, Randomized, Double-blind, Sham-controlled Multi-center Clinical Study Assessing the Safety and Efficacy of Nerivio for the Preventive Treatment of Migraine
Migraine is a common neurologic with attacks of headache and associated symptoms such as nausea, vomiting, phono and photophobia. Migraine can lead to substantial functional impairment. This study intends to demonstrate the safety and efficacy of the Nerivio for migraine prevention.
The study is a prospective, randomized, double-blind, sham-controlled, multicenter study, conducted in three phases.
The study will consist of a screening/enrollment visit, followed by a 4-week (28 days) baseline phase, an 8-week double-blind preventive treatment phase, and a 4-week open-label phase.
Patients will complete an electronic diary throughout the study; this includes a daily evening report (completed regardless of whether the patient had a headache) and treatment feedback during the follow-up pre-emptive phase.
The primary endpoint is the mean change in the average of migraine headache days per month comparing the 4-week baseline phase (weeks 1 through 4) with the last 28 days of the treatment phase (weeks 9 through 12).
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Nerivio is a neuromodulation device approved for the acute treatment of migraine with or without aura in patients 12 years of age or older. The device utilizes electro stimulation to achieve conditioned pain modulation (CPM). CPM stimulate endogenous analgesic mechanism. Treatments are self-administered by the user at the onset of a migraine attack. this study intends to demonstrate the safety and efficacy of the Nwrivio for migraine prevention.
The study is a prospective, randomized, double-blind, sham-controlled, multicenter trial, conducted in three phases. The ratio between treatment and control groups will be 1:1, stratified by center and patient type (chronic/non-chronic). The study will consist of a screening/enrollment visit, followed by a 4-week (28 days) baseline phase. Eligible participants will enter an 8-week double-blind preventive treatment phase. Following the preventive treatment phase, patients will be offered to participate in a 4-week open-label pre-emptive treatment phase or continue their prevention treatment with an active device, according to their eligibility.
Patients will complete an electronic diary throughout the study; this includes a daily evening report (completed regardless of whether the patient had a headache) and treatment feedback during the follow up pre-emptive phase
Phase I - Baseline - 4 weeks (weeks 1 through 4):
Eligible participants will install the Nerivio app on their smartphones and will be instructed to record daily their migraine/headaches symptoms and medication use on the Nerivio app.
Transition to the treatment phase: Participants who meet the following criteria in the baseline phase will be eligible to continue to the treatment phase:
- Complete the diary in at least 22 out of the 28 days during the baseline phase (80%)
- Have between 6 to 24 headache days during the 28-day baseline period
- At least 4 of their headache days during the baseline phase fulfill the International Classification of Headache Disorders 3rd edition (ICHD-3) criteria for migraine (migraine without aura [code 1.1; C and D] or with aura [code 1.2; B and C], or probable migraine, or headaches requiring the use of migraine-specific medications including triptans, gepants or ergot derivatives).
Phase II - treatment phase (prevention) - 8 weeks (weeks 5 through 12):
Participants who meet the baseline phase requirements will be randomized in a 1:1 ratio to active and sham groups. Participants will be instructed to complete a daily diary (in the Nerivio app) about their headaches, associated symptoms, and medication use. They will also be instructed to conduct a 45-minute treatment with Nerivio every other day.
Transition to the follow-up phase (open label):
At the end of the treatment phase, participants from both arms (active and sham) may continue to a follow-up phase in which they will receive an active device that can be used during this phase. The data of all participants will be used for safety analyses.
The data of participants from the baseline and treatment phases will be used to assess their eligibility to participate in the pre-emptive follow-up phase. Participants eligible for the follow-up phase meet the following conditions:
- Between 6-16 headache days during the baseline phase.
- Participants experience prodrome symptoms within 24 hours prior to the onset of their migraine headache in at least half of their migraine attacks during the baseline phase.
- Participants completed the daily questionnaires in at least 70% of the days during the treatment phase.
- Treated every other day in at least 24 and less than 33 days during the 56 days of the treatment phase.
All adverse events will be reported.
Phase III - Follow-up phase (open label) - 4 weeks (weeks 13 through 16):
All participants will receive an active Nerivio device to use during the follow-up phase. Participants who do not meet the above requirements will be able to enter into the safety follow-up and continue to use Nerivio every other day for the preventive treatment of migraine. They will be instructed to compete a daily diary as was done in the treatment phase.
Participants who meet the above requirements will enter the pre-emptive follow-up phase and be instructed to conduct a 45-minute device treatment within 60 minutes of prodrome symptom onset. Participants will be instructed to complete questionnaires regarding their headache, prodrome symptoms, and medication use at baseline (start of treatment), 2 hours post-treatment, and 24 hours post-treatment. In addition, participants will be instructed to continue to report the daily diary, as performed in the other phases of the study.
All adverse events will be reported.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85013
- Evolve Clinical Research
-
-
California
-
Carlsbad, California, United States, 92011
- The Neurology Center of Southern California
-
Newport Beach, California, United States, 92663
- Newport Beach Clinical Research Associates
-
-
Connecticut
-
Hartford, Connecticut, United States, 06107
- Hartford Headache Center
-
-
Florida
-
Boynton Beach, Florida, United States, 33472
- Reciomed Clinical Research
-
Cutler Bay, Florida, United States, 33157
- Beautiful Minds Clinical Research Center
-
-
Illinois
-
Chicago, Illinois, United States, 60657
- Chicago Headache Center and Research Institute
-
-
Indiana
-
Evansville, Indiana, United States, 47713
- Deaconess Clinic
-
-
Kentucky
-
Paducah, Kentucky, United States, 42001
- Four Rivers Clinical Research
-
-
Mississippi
-
Ridgeland, Mississippi, United States, 39157
- Headache Neurology Research Institute
-
-
Missouri
-
Saint Peters, Missouri, United States, 63303
- StudyMetrix Research
-
Springfield, Missouri, United States, 65810
- Clinvest Research
-
-
New Jersey
-
Toms River, New Jersey, United States, 08755
- Ocean Medical Research
-
-
New York
-
Amherst, New York, United States, 14226
- Dent Neurosciences Research Center
-
-
South Carolina
-
Columbia, South Carolina, United States, 29203
- Prevention & Strengthening Solutions, Inc.
-
-
West Virginia
-
Morgantown, West Virginia, United States, 26506
- West Virginia University Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18-75 years old.
- Must have at least a 6-month history of headaches that meet the ICHD-3 diagnostic criteria for migraine with or without aura, either chronic (at least 15 days of Headache Days(HD)/ month with migraine days (migraine with or without aura) at least 8 days/ month for > 3 months) or non-chronic migraine.
- History of 6 to 24 headache days per 28-day period for each of the 3 months preceding study enrolment (based on participant report).
- Subject on prophylactic migraine treatment are permitted to remain on 1 medication with possible migraine-prophylactic effects if the dose has been stable for at least 2 months prior to the screening visit, and the dose is not expected to change during the course of the study.
- Have personal access to a smartphone (24/7).
- Must be able and willing to comply with the protocol.
- Must be able and willing to provide informed consent..
Exclusion Criteria:
- An active implanted electrical and/or neurostimulator device (e.g. cardiac pacemaker, cochlear implant).
- Uncontrolled epilepsy.
- History of use of opioids or barbiturates on more than 4 days a month in the last 6 months.
- Current participation in any other interventional clinical study
- Subject without basic cognitive and motor skills required for operating a smartphone.
- Pregnant or breastfeeding.
- Other significant pain, medical or psychological problems that in the opinion of the investigator may confound the study assessments.
- Prior experience with the Nerivio device.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Migraine prevention treatment with active Nerivio
Participants will treat with an active Nerivio device every other day for migraine prevention.
|
Nerivio neurostimulator of conditional pain modulation (CPM)
|
Sham Comparator: Migraine prevention treatment with sham Nerivio
Participants will treat with a sham (placebo) Nerivio device every other day for migraine prevention.
|
Nerivio neurostimulator with an electrical output not intended for neurostimulation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction in Migraine Days
Time Frame: 3 months
|
The mean reduction in the number of migraine days per month during the last 28 days (4 weeks) of the treatment phase (weeks 9 through 12) compare to the 4-week baseline phase (weeks 1 through 4) A migraine day is defined as a calendar day with a headache that is accompanied by at least one of the following symptoms: aura, photophobia, phonophobia, nausea and/or vomiting; or a calendar day with a headache that is treated with a migraine-specific acute medication. |
3 months
|
Rate of Adverse Events (Safety and Tolerability)
Time Frame: 3 months
|
Number of participants with Adverse Events (AE), Serious Adverse Events (SAE) and Device-related Adverse Events
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction in Moderate/Severe Headache Days
Time Frame: 3 months
|
The mean reduction in the number of moderate/severe headache days per month during the last 28 days (4 weeks) of the treatment phase (weeks 9 through 12) compare to the 4-week baseline phase (weeks 1 through 4) A moderate/severe headache day is defined as a calendar day with a moderate or severe headache. |
3 months
|
Reduction Headache Days
Time Frame: 3 months
|
The mean reduction in the number of headache days per month during the last 28 days (4 weeks) of the treatment phase (weeks 9 through 12) compare to the 4-week baseline phase (weeks 1 through 4) A headache day is defined as a calendar day with headache (at any severity). |
3 months
|
Reduction of 50% in Headache Days
Time Frame: 3 months
|
Percentage of patients achieving at least 50% reduction from baseline in the mean number of headache days (all severities) per month in the last 4 weeks of the treatment phase (weeks 9 through 12).
|
3 months
|
Increase in Headache Impact Test-6 (HIT-6) Score at the End of the Last 28 Days (4 Weeks) of the Treatment Phase (Weeks 9 Through 12) Compare to the HIT-6 Score at the End of the 4-week Baseline Phase (Weeks 1 Through 4)
Time Frame: 3 months
|
Headache Impact Test-6 (HIT-6) questionnaire is a tool used to measure the impact headaches have on your ability to function on the job, at school, at home, and in social situations.
the questionnaire contains 6 questions with a total score between 36 to 78.
Higher score interpret as better patient outcome.
|
3 months
|
Reduction in Migraine-Specific Quality-of-Life (MSQ) Questionnaire Score at the End of the Last 28 Days (4 Weeks) of the Treatment Phase (Weeks 9 Through 12) Compare to the MSQ Score at the End of the 4-week Baseline Phase (Weeks 1 Through 4)
Time Frame: 3 months
|
The migraine Specific Quality-of-Life questionnaire (MSQ) is a tool to measure the impact of migraine on your ability to function on the job, at school, at home, and in social situations.
The questionnaire contains 14 questions with a total score between 0 to 84.
Lower score interprets as better patient outcome.
|
3 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction in Migraine Medication Intake
Time Frame: 3 months
|
Reduction in the mean number of acute headache/migraine medication days per month in the last 4 weeks of the treatment phase (weeks 9 through 12) compared to baseline (weeks 1 through 4).
|
3 months
|
Percentage of Freedom From Headache Post 2 Hours Following Prodrome Treatment
Time Frame: 2 hours post treatment at follow up phase
|
Percentage of participants who treat for the first treatment in the pre-emptive phase, during the prodrome, when they are pain-free, and remain pain-free during the following 2 hours after the treatment, without use of acute medication.
|
2 hours post treatment at follow up phase
|
Percentage of Freedom From Headache Post 24 Hours Following Prodrome Treatment
Time Frame: 24 hours post treatment at follow up phase
|
Percentage of participants who treat for the first treatment in the pre-emptive phase, during the prodrome, when they are pain-free, and remain pain-free during the following 24 hours after the treatment, without use of acute medication.
|
24 hours post treatment at follow up phase
|
Percentage of Reduction of Headache Post 24 Hours From Prodrome Treatment
Time Frame: 24 hours post treatment at follow up phase
|
Percentage of patients who treat during the prodrome, when they are pain free, and remain either pain free or with mild pain during the following 24 hours after the treatment without use of acute medication.
|
24 hours post treatment at follow up phase
|
Feasibility of Migraine Prediction Algorithm
Time Frame: 3 months
|
Analysis of the daily information provided by the participants for the purpose of predicting their migraine days
|
3 months
|
Health Economic Analysis
Time Frame: 12 weeks
|
Health economics analysis of the difference between subjects using Nerivio as a therapy and those who do not with respect to:
|
12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Robert Cowan, MD, Stanford Health Care
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TCH008
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Migraine
-
Austrian Migraine Registry CollaborationMedical University of Vienna; Medical University Innsbruck; Austrian Headache...RecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineAustria
-
Tonix Pharmaceuticals, Inc.PremierCompletedChronic Migraine | Chronic Migraine, Headache | Chronic Migraine Without Aura | Aura MigraineUnited States
-
Harvard University Faculty of MedicineBrigham and Women's Hospital; Palmer Center for Chiropractic Research (PCCR)CompletedMigraine | Migraine Disorders | Migraine Without Aura | Migraine With Aura | Migraine, ClassicUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
CoolTech LLCTerminatedMigraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
Notre-Dame Hospital, Montreal, Quebec, CanadaAllerganCompletedChronic Migraine | Migraine Without Aura | Migraine With AuraCanada
-
Glostrup University Hospital, CopenhagenUnknownChronic Migraine | Migraine Without Aura | Migraine With AuraDenmark
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...CompletedMigraine With Aura | Migraine in ChildrenItaly
-
The Cleveland ClinicWithdrawnMigraine | Migraine Disorders | Headache Disorders, Primary | Migraine Headache | Migraine Without Aura | Migraine With Aura | Headache, MigraineUnited States
Clinical Trials on Nerivio active device
-
TheranicaRambam Health Care Campus; Northwell HealthCompletedMigraine Without Aura | Migraine With AuraUnited States, Israel
-
TheranicaCompletedMigraine Without Aura | Migraine With AuraIsrael
-
TheranicaTerminated
-
TheranicaActive, not recruiting
-
Children's National Research InstituteTheranicaRecruitingNew Daily Persistent Headache (NDPH)United States
-
TheranicaCompleted
-
TheranicaCompletedMenstrual MigraineUnited States
-
TheranicaNot yet recruitingMigraine in Children
-
Cedars-Sinai Medical CenterNational Institutes of Health (NIH); Indiana UniversityRecruitingAtrial FibrillationUnited States
-
ReShape LifesciencesUnknownObesityUnited States, Australia